SRR2016941
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.380
- G2M_CHECKPOINT+0.340
- SPERMATOGENESIS+0.280
- E2F_TARGETS+0.270
- MITOTIC_SPINDLE+0.260
- CHOLESTEROL_HOMEOSTASIS+0.240
- PANCREAS_BETA_CELLS+0.230
- HEDGEHOG_SIGNALING+0.200
- UV_RESPONSE_DN+0.200
- IL6_JAK_STAT3_SIGNALING+0.190
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.460
- P53_PATHWAY-0.320
- MYC_TARGETS_V2-0.260
- ADIPOGENESIS-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- BILE_ACID_METABOLISM-0.210
- FATTY_ACID_METABOLISM-0.200
- TNFA_SIGNALING_VIA_NFKB-0.180
- HYPOXIA-0.160
- PEROXISOME-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296088 | — | cohortMD2 | 0.718 |
| 2 | SRR5088820 | — | — | 0.704 |
| 3 | SRR12475122 | — | — | 0.679 |
| 4 | MDT-AP-3043 | Med | Medulloblastoma | 0.672 |
| 5 | SRR17866841 | — | — | 0.669 |
| 6 | SRR4195679 | — | — | 0.666 |
| 7 | SRR10899955 | — | — | 0.665 |
| 8 | MDT-AP-3263 | Med | Medulloblastoma | 0.653 |
| 9 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.648 |
| 10 | TCGA-CU-A3KJ-01A-11R-A21D-07 | — | — | 0.648 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |